Orbital exenteration for advanced periorbital non-melanoma skin cancer

Prognostic factors and survival

R. C. Gerring, C. T. Ott, J. M. Curry, Zoukaa B Sargi, Sara Wester

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Purpose To describe prognostic factors and survival outcomes in patients who underwent orbital exenteration for periocular nonmelanoma cutaneous malignancies. Methods The authors performed an institutional review board-approved retrospective review of all patients who underwent orbital exenteration for nonmelanoma periocular cutaneous malignancies at a tertiary care hospital system over a 10-year period. Patient demographics, tumor, and treatment data were recorded. Survival outcomes included disease-free survival (DFS) and overall survival (OS). Log-rank tests were used to test for difference in survival curves among various potential prognostic indicators, and multivariate analysis was performed using Cox's proportional hazards model. Results Forty-nine patients with an average age of 70.3 years were followed with a median follow-up of 17.5 months. At 2 years the OS was 78% while the DFS was 61%. The mean DFS for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous gland carcinoma (SGC) were 52.6, 39.2 and 28.1 months, respectively. Multivariate analysis demonstrated that only positive final surgical margin was predictive of worse outcome (P=0.002). Recurrences were most frequent in the first 2 years. Conclusions Despite the relatively more aggressive nature of periocular malignancies that have invaded the orbit, orbital exenteration offers an overall 2-year DFS of ~ 60%. BCC had the greatest mean survival time, however this was not statistically significant. We found worse prognosis with positive final surgical margins and recommend a multidisciplinary surgical approach to achieve complete resection when indicated.

Original languageEnglish (US)
Pages (from-to)379-388
Number of pages10
JournalEye (Basingstoke)
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Skin Neoplasms
Disease-Free Survival
Survival
Basal Cell Carcinoma
Neoplasms
Multivariate Analysis
Sebaceous Glands
Skin
Research Ethics Committees
Orbit
Tertiary Healthcare
Proportional Hazards Models
Tertiary Care Centers
Squamous Cell Carcinoma
Survival Rate
Demography
Orbital
Cancer
Carcinoma
Recurrence

ASJC Scopus subject areas

  • Ophthalmology
  • Arts and Humanities(all)

Cite this

Orbital exenteration for advanced periorbital non-melanoma skin cancer : Prognostic factors and survival. / Gerring, R. C.; Ott, C. T.; Curry, J. M.; Sargi, Zoukaa B; Wester, Sara.

In: Eye (Basingstoke), Vol. 31, No. 3, 01.03.2017, p. 379-388.

Research output: Contribution to journalReview article

@article{33fc06caf44c459786a0f990d30f1738,
title = "Orbital exenteration for advanced periorbital non-melanoma skin cancer: Prognostic factors and survival",
abstract = "Purpose To describe prognostic factors and survival outcomes in patients who underwent orbital exenteration for periocular nonmelanoma cutaneous malignancies. Methods The authors performed an institutional review board-approved retrospective review of all patients who underwent orbital exenteration for nonmelanoma periocular cutaneous malignancies at a tertiary care hospital system over a 10-year period. Patient demographics, tumor, and treatment data were recorded. Survival outcomes included disease-free survival (DFS) and overall survival (OS). Log-rank tests were used to test for difference in survival curves among various potential prognostic indicators, and multivariate analysis was performed using Cox's proportional hazards model. Results Forty-nine patients with an average age of 70.3 years were followed with a median follow-up of 17.5 months. At 2 years the OS was 78{\%} while the DFS was 61{\%}. The mean DFS for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous gland carcinoma (SGC) were 52.6, 39.2 and 28.1 months, respectively. Multivariate analysis demonstrated that only positive final surgical margin was predictive of worse outcome (P=0.002). Recurrences were most frequent in the first 2 years. Conclusions Despite the relatively more aggressive nature of periocular malignancies that have invaded the orbit, orbital exenteration offers an overall 2-year DFS of ~ 60{\%}. BCC had the greatest mean survival time, however this was not statistically significant. We found worse prognosis with positive final surgical margins and recommend a multidisciplinary surgical approach to achieve complete resection when indicated.",
author = "Gerring, {R. C.} and Ott, {C. T.} and Curry, {J. M.} and Sargi, {Zoukaa B} and Sara Wester",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/eye.2016.218",
language = "English (US)",
volume = "31",
pages = "379--388",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Orbital exenteration for advanced periorbital non-melanoma skin cancer

T2 - Prognostic factors and survival

AU - Gerring, R. C.

AU - Ott, C. T.

AU - Curry, J. M.

AU - Sargi, Zoukaa B

AU - Wester, Sara

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose To describe prognostic factors and survival outcomes in patients who underwent orbital exenteration for periocular nonmelanoma cutaneous malignancies. Methods The authors performed an institutional review board-approved retrospective review of all patients who underwent orbital exenteration for nonmelanoma periocular cutaneous malignancies at a tertiary care hospital system over a 10-year period. Patient demographics, tumor, and treatment data were recorded. Survival outcomes included disease-free survival (DFS) and overall survival (OS). Log-rank tests were used to test for difference in survival curves among various potential prognostic indicators, and multivariate analysis was performed using Cox's proportional hazards model. Results Forty-nine patients with an average age of 70.3 years were followed with a median follow-up of 17.5 months. At 2 years the OS was 78% while the DFS was 61%. The mean DFS for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous gland carcinoma (SGC) were 52.6, 39.2 and 28.1 months, respectively. Multivariate analysis demonstrated that only positive final surgical margin was predictive of worse outcome (P=0.002). Recurrences were most frequent in the first 2 years. Conclusions Despite the relatively more aggressive nature of periocular malignancies that have invaded the orbit, orbital exenteration offers an overall 2-year DFS of ~ 60%. BCC had the greatest mean survival time, however this was not statistically significant. We found worse prognosis with positive final surgical margins and recommend a multidisciplinary surgical approach to achieve complete resection when indicated.

AB - Purpose To describe prognostic factors and survival outcomes in patients who underwent orbital exenteration for periocular nonmelanoma cutaneous malignancies. Methods The authors performed an institutional review board-approved retrospective review of all patients who underwent orbital exenteration for nonmelanoma periocular cutaneous malignancies at a tertiary care hospital system over a 10-year period. Patient demographics, tumor, and treatment data were recorded. Survival outcomes included disease-free survival (DFS) and overall survival (OS). Log-rank tests were used to test for difference in survival curves among various potential prognostic indicators, and multivariate analysis was performed using Cox's proportional hazards model. Results Forty-nine patients with an average age of 70.3 years were followed with a median follow-up of 17.5 months. At 2 years the OS was 78% while the DFS was 61%. The mean DFS for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and sebaceous gland carcinoma (SGC) were 52.6, 39.2 and 28.1 months, respectively. Multivariate analysis demonstrated that only positive final surgical margin was predictive of worse outcome (P=0.002). Recurrences were most frequent in the first 2 years. Conclusions Despite the relatively more aggressive nature of periocular malignancies that have invaded the orbit, orbital exenteration offers an overall 2-year DFS of ~ 60%. BCC had the greatest mean survival time, however this was not statistically significant. We found worse prognosis with positive final surgical margins and recommend a multidisciplinary surgical approach to achieve complete resection when indicated.

UR - http://www.scopus.com/inward/record.url?scp=85044562541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044562541&partnerID=8YFLogxK

U2 - 10.1038/eye.2016.218

DO - 10.1038/eye.2016.218

M3 - Review article

VL - 31

SP - 379

EP - 388

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

IS - 3

ER -